EP1567138A1 - Use of diamide derivatives for inhibiting chronic tissue transplant rejection - Google Patents
Use of diamide derivatives for inhibiting chronic tissue transplant rejectionInfo
- Publication number
- EP1567138A1 EP1567138A1 EP03783726A EP03783726A EP1567138A1 EP 1567138 A1 EP1567138 A1 EP 1567138A1 EP 03783726 A EP03783726 A EP 03783726A EP 03783726 A EP03783726 A EP 03783726A EP 1567138 A1 EP1567138 A1 EP 1567138A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- substituted
- alkyl
- group
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 55
- 206010052779 Transplant rejections Diseases 0.000 title claims abstract description 40
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 14
- 150000001470 diamides Chemical class 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- -1 1,2-diphenylethyl Chemical group 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 16
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000003107 substituted aryl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 4
- 229910006069 SO3H Inorganic materials 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001154 acute effect Effects 0.000 abstract description 24
- 210000001519 tissue Anatomy 0.000 description 32
- 210000000056 organ Anatomy 0.000 description 28
- 210000002216 heart Anatomy 0.000 description 23
- 238000001356 surgical procedure Methods 0.000 description 20
- 229940125904 compound 1 Drugs 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 12
- 238000009472 formulation Methods 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 229940124589 immunosuppressive drug Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000002674 obstructive nephropathy Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- IYTJRMRETHPZAC-UHFFFAOYSA-N 4,4-dibenzylpiperidine Chemical compound C1CNCCC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 IYTJRMRETHPZAC-UHFFFAOYSA-N 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Acute transplant rejection occurs as a result of the immune system of the transplant recipient attacking the transplanted tissue.
- Acute rejection is rapid, generally occurs within hours to weeks after transplant of the tissue and can typically be suppressed with the use of immunosuppressive drugs such as cyclosporin A.
- immunosuppressive drugs such as cyclosporin A.
- chronic rejection occurs over time, typically several months to years after engraftment, even in the presence of successful immunosuppression. It involves multiple factors and processes of the host and is usually the result of a prolonged process of wound healing the host undergoes post-transplant. Therefore, chronic rejection is not totally immuno logical in origin and additional causes(s) are not fully understood. They may include ischemic insult, denervation of the transplanted tissue, hyperlipidemia and hypertension associated with immunosuppressive drugs. For most organs, the most definitive way of showing that rejection is occurring is by biopsy of that organ. For practical reasons, however, biopsies are not always done and are particularly less practical when chronic rejection is suspected.
- Chronic rejection of a transplant organ is generally characterized as failure of the organ after it has begun to perform its function in the recipient or host.
- Chronic rejection is commonly monitored by a decrease in organ function which, if unarrested, results in failure of the organ, infection, and necrosis of organ tissue.
- Chronic rejection is identified, commonly too late for treatment that can save the transplant, by pathogenic f ⁇ brosis, which is characterized by extensive deposition of the extracellular matrix proteins: collagen, fibronectin, and elastin, and by emergence of cells with the myof ⁇ broblast phenotype. Fibrosis becomes a telltale characteristic of chronic rejection where fibrogenesis is observed to damage organ microstructures or to block passages that need to remain open for organ function.
- the chronic rejection process is not inhibited by any known therapeutic regimen at this time. Moreover, as noted above, it is sometimes difficult to detect and treat in a time frame that will save the transplant. Thus, additional improvements in the long-term survival of organ transplant patients are dependent on the development of new techniques for managing chronic transplant rejection.
- the present invention is a method of inhibiting tissue transplant rejection in a subject with a tissue transplant.
- the method is effective against both acute and chronic rejection of transplanted tissue, but is particularly advantageous in inhibiting chronic transplant rejection.
- the method comprises the step of administering to the subject an effective amount of a compound represented by Formula (I):
- Ri is a substituted or unsubstituted aryl group or a substituted or unsubstituted alkyl group.
- R 2 is an optionally substituted aralkyl group or an alkyl group substituted with -NR 5 R 6 .
- R 3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group.
- P a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group.
- R 5 and R$ are independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group or R 5 and R taken together with the nitrogen to which they are attached are a non-aromatic heterocyclic group.
- the disclosed method can be advantageously used to treat chronic rejection of transplanted tissue, a condition for which heretofore effective treatments were unavailable. Additionally, acute rejection of transplanted tissue can also be inhibited with the disclosed method.
- Figure 1 is a graph showing inhibition of chronic vasculopathy in transplanted hearts in a model consisting of only MHC class II mismatched mice at eight weeks following heart transplant.
- the graph compares inhibition of chronic vasculopathy in a group of mice treated with 75 mg/kg of Compound 1 subcutaneously for fourteen days after heart transplant surgery with an untreated control group.
- the scores shown in the graph range from zero to five to indicate the severity of chronic rejection accelerated atherosclerosis, with zero being normal blood vessel and five being fully occluded.
- Figure 2 is a graph showing inhibition of chronic vasculopathy in transplanted hearts in a model consisting of only fully mismatched mice greater than 100 days following heart transplant.
- the graph compares inhibition of chronic vasculopathy in a group of mice treated with a single 250 ⁇ m dose of anti-CD 154 monoclonal antibody immediately following heart transplant surgery with a group of mice treated with a single 250 ⁇ m dose of anti-CD154 immediately following heart transplant surgery and 75 mg/kg of Compound 1 subcutaneously for fourteen days after heart transplant surgery.
- the scores shown in the graph range from zero to five to indicate the severity of chronic rejection accelerated atherosclerosis, with zero being normal blood vessel and five being fully occluded.
- Disclosed herein is a method of treating (preventing, inhibiting or suppressing) rejection of transplanted tissue in a recipient subject.
- the method is particularly effective in treating (preventing, inhibiting or suppressing) chronic transplant rejection.
- the disclosed method can also be used to treat (prevent, inhibit or suppress) acute transplant rejection.
- Acute transplant rejection is the rejection by the immune system of a tissue transplant recipient when the transplanted tissue is immunologically foreign. Acute rejection is characterized by infiltration of the transplanted tissue by immune cells of the recipient, which carry out their effector function and destroy the transplanted tissue. The onset of acute rejection is rapid and generally occurs in humans within a few weeks after transplant surgery. Generally, acute rejection can be inhibited or suppressed with immunosuppressive drugs such as rapamycin, cyclosporin A, anti-CD40L monoclonal antibody and the like. "Chronic transplant rejection” generally occurs in humans within several months to years after engraftment, even in the presence of successful immunosuppression of acute rejection.
- Fibrosis is a common factor in chronic rejection of all types of organ transplants.
- Chronic rejection can typically be described by a range of specific disorders that are characteristic of the particular organ.
- disorders include fibroproliferative destruction of the airway (bronchiolitis obliterans); in heart transplants or transplants of cardiac tissue, such as valve replacements, such disorders include fibrotic atherosclerosis; in kidney transplants, such disorders include, obstructive nephropathy, nephrosclerorsis, tubulointerstitial nephropathy; and in liver transplants, such disorders include disappearing bile duct syndrome.
- Chronic rejection can also be characterized by ischemic insult, denervation of the transplanted tissue, hyperlipidemia and hypertension associated with immunosuppressive drugs.
- transplant rejection encompasses both acute and chrome transplant rejection.
- the disclosed methods can be advantageously used to inhibit or suppress transplant rejection, preferably chronic rejection, in a mammal with an organ or tissue transplant.
- transplant rejection preferably chronic rejection
- the most common type of transplant is an allograft, which is a graft between members of the same species.
- the transplanted tissue or organ is bio-engineered, e.g., when the transplanted tissue or organ is grown from a stem cell or other type of precursor cell(s).
- Bio-engineered tissues or organs can be grown outside of the body and transplanted directly into the host.
- the precursor cells or immature organ or tissue is transplanted into the host to grow and mature.
- the disclosed method can also be used to treat tranplant rejection when the tranplanted organ or tissue is a xenograft, i.e., the donor is a member of a species different than the recipient.
- Xenografts are advantageously used with a bio- engineered tissue or organ, which, instead of being transplanted directly into the recipient in need of the tissue or organ, can be transplanted into a surrogate host such as non-human mammal until a suitable human recipient in need of the bio- engineered tissue or organ is identified.
- the tissue or organ can be transplanted into the surrogate to allow the bio-engineered tissue or organ to mature.
- surrogate hosts may be preferred in instances where further development of the tissue or organ is required before transplantation into a human recipient.
- a xenograft is used when a suitable allograft donor is unavailable.
- the host is selected to minimize transmission of communicable diseases.
- aryl group refers to carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, isoimidazolyl, thienyl, furanyl, pyridyl, pyrimidyl, pyranyl, pyrazolyl, pyrrolyl, pyrazinyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, and tetrazolyl.
- aryl group used alone or as part of a larger moiety such as “aralkyl”, also includes fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings.
- Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazolyl, quinoxalinyl, quinazolinyl, benzoisothiazolyl, benzooxazolyl, benzoisooxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl and isoindolyl.
- aryl group used alone or as part of a larger moiety such as “aralkyl”, also includes carbocylic aromatic rings or heteroaryl aromatic rings fused to a cycloalkyl group or an non-aromatic heterocyclic group. Examples include indanyl, tetrahydronaphthyl and fluorenyl.
- alkyl group e.g., the alkyl groups represented by R 1 -R- 5
- aralkyl e.g., the aralkyl group represented by R 2
- cycloalkylalkyl is a straight, branched or cyclic non- aromatic hydrocarbon which is completely saturated.
- a straight or branched alkyl group has from 1 to about 10 carbon atoms, preferably from 1 to about 4, and a cyclic aliphatic group has from 3 to about 10 carbon atoms, preferably from 3 to about 8.
- suitable straight or branched alkyl group examples include methyl, ethyl, n-propyl, ts ⁇ -propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl; and examples of suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- a C1-C10 straight or branched alkyl group or a C3-C8 cyclic alkyl group are also referred to as a "lower alkyl" group.
- aralkyl group is an alkyl group substituted with one or more aryl groups.
- a “substituted aralkyl group” can have one or more substituents on the alkyl part of the aralkyl group and/or on the aryl part of the aralkyl group. Suitable aralkyl group substituents are described below in the section providing examples of aryl group substituents and alkyl group substituents.
- heteroaralkyl group is an alkyl group substituted with one or more heteroaryl groups.
- a “substituted heteroaralkyl group” can have one or more substituents on the alkyl part of the heteroaralkyl group and/or on the heteroaryl part of the heteroaralkyl group. Suitable heteroaralkyl group substituents are described below in the section providing examples of aryl group substituents and alkyl group substituents.
- a “cycloalkylalkyl group” is an alkyl group substituted with one or more cycloalkyl groups.
- a “substituted cycloalkylalkyl group” can have one or more substituents on the alkyl part or cycloalkylalkyl part of the cycloalkylalkyl group. Suitable cycloalkylalkyl group substituents are described below in the section providing examples of alkyl group substituents.
- heterocycloalkylalkyl group is an alkyl group substituted with one or more non-aromatic heterocyclic groups.
- a “substituted heterocycloalkylalkyl group” can have one or more substituents on the alkyl part or non-aromatic heterocyclic part of the heterocycloalkylalkyl group. Suitable heterocycloalkylalkyl group substituents are described below in the section providing examples of alkyl group substituents and non-aromatic heterocyclic group substitutents.
- non-aromatic heterocyclic ring refers to non-aromatic ring systems typically having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S.
- non-aromatic heterocyclic rings examples include 3-lH-benzimidazol-2-one, 3- tefrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [l,3]-dioxalanyl, [l,3]-dithiolanyl, [l,3]-dioxanyl, 2-tetrahydrothiophenyl, 3- tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2- thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2- pyrrolidinyl, 3-pyrorolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2- piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazol
- Suitable substituents for an alkyl group, for a carbon atom on an aryl group or a non-aromatic heterocyclic group are those which do not substantially interfere with the ability of the compound to inhibit transplant rejection.
- suitable substituents for a carbon atom of an aryl, alkyl or a carbon atom of a non-aromatic heterocyclic group include -OH, halogen (-Br, -CI, -I and -F), R, -CH 2 R, -OCH 2 R, -CH 2 OC(O)R, -OR, -O-COR, -COR, -CN, -NO 2 , -COOH, -SO 3 H, -NH 2 , -NHR, - N(R) 2 , -COOR, -CHO, -CONH 2 , -CONHR, -CON(R) 2 , -NHCOR, -NRCOR, -NHCONH 2 , -NH
- Each R is independently an alkyl, substituted alkyl, benzyl, substituted benzyl, aryl or substituted aryl group.
- R is an alkyl, benzylic or aryl group.
- -N(R) 2 taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group, such as pyrollidinyl, piperidinyl, morpholinyl and thiomorpholinyl.
- substituents on the alkyl, aryl or benzyl group represented by R include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- a substituted aryl, alkyl and non- aromatic heterocyclic group can have more than one substitutent.
- substituents on the aliphatic group or the phenyl ring represented by R' include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- pharmaceutically acceptable salts of the disclosed compounds can be used in the disclosed methods.
- an acid salt of a compound containing an amine or other basic group can be obtained, by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
- a suitable organic or inorganic acid such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
- Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
- Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g.
- Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base.
- Such a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, 2- hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, N-benzyl- ⁇ -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.
- an "effective amount" according to the present invention of a compound of Formula (I) is the quantity which, when administered to a transplant recipient, inhibits or suppresses transplant rejection, i.e., delays the onset of and/or reduces the severity of one or more of the symptoms associated with transplant rejection, and preferably with chronic transplant rejection.
- the amount of the disclosed compound to be administered to a transplant recipient will depend on the type of transplant, the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective amounts of the disclosed compounds typically range between about 0.01 mg/kg per day and about 100 mg/kg per day, and preferably between 0.1 mg/kg per day and about 10 mg/kg/day.
- a "subject” is a mammal, preferably a human, but can also be an animal who has received a tissue transplant and is in need of treatment to inhibit transplant rejection, and preferably chronic transplant rejection.
- recipient animals in need of such treatment include, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- the use of the disclosed compounds to inhibit transplant rejection is not limited to any particular organ or tissue type.
- the disclosed treatment is effective, but not limited to, inhibiting rejection of transplanted heart, kidney, lung, liver, pancreas, pancreatic islets, brain tissue, stomach, large intestine, small intestine, cornea, skin, trachea, bone, bone marrow, muscle, bladder or parts thereof.
- the compounds described herein, and the pharmaceutically acceptable salts thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
- suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
- the compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19 th edition, Mack Publishing Co., Easton, PA (1995).
- the disclosed compounds or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.
- the tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch or alginic acid; a lubricant such as magnesium stearate; and/or a sweetening agent such as sucrose, lactose or saccharin.
- a binder such as gum tragacanth, acacias, corn starch or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch or alginic acid
- a lubricant such as magnesium stearate
- a dosage unit form When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Narious other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both.
- a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
- aqueous or organic media for parental administration of the disclosed compounds, or salts thereof, can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
- solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the compounds may also be formulated as a depot preparation.
- Suitable formulations of this type include biocompatible and biodegradable polymeric hydrogel formulations using crosslinked or water insoluble polysaccharide formulations. Also included are polymerizable polyethylene oxide formulations. Formulations of this type are disclosed in U.S. Patent ⁇ os. 5,410,016, 4,713,448, 4,636,524, 6,083,524, 5,785,993, 4,937,270 and 5,017,229, the entire teachings of which are incorporated herein by reference. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection.
- the compounds are implanted in the microenvironment of the transplanted organ or tissue.
- the compounds may be formulated with suitable polymeric or hydrophobic materials, for example, as an emulsion in an acceptable oil, or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- Preferably disclosed compounds or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal.
- the unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IN bag, a tablet, or a vial.
- the quantity of active ingredient (viz., a compound of Formula I or salts thereof) in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient.
- the dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
- the compound used in the method of the present invention can be advantageously co-administered with immunosuppressive drugs.
- immunosuppressive drugs examples include corticosteroids, cyclosporin A, rapamycin and FK506 or antibody therapies such as anti T-cell antibodies. It is particularly useful to co-administer a compound represented by Formula (I) with rapamycin or anti-CD40L monoclonal antibody.
- the variables for the compound represented by Formula (I) are as provided above, provided that the compound is characterized by one or more of the following features: a) Ri is an optionally substituted aryl group or an optionally substituted Ci- C 4 aralkyl group. b) Ri is an optionally substituted phenyl group or an optionally substituted phenyl-C ⁇ -C alkyl group. Preferred substituents for these values of Ri include C ⁇ -C alkyl, C ⁇ -C 4 alkoxy, halogen, CN, C ⁇ -C 4 -alkylthiol, -C 4 - haloalkyl and phenoxy.
- R 2 is an optionally substituted heteroaralkyl group or an alkyl group substituted with -NR 5 R 6 .
- R 2 is an optionally substituted imadazolyl-C ⁇ -C 4 -alkyl group or a C ⁇ -C alkyl group substituted with -NRsR ⁇ .
- R 2 is an optionally substituted 2-(imidazol-4-yl)ethyl, an optionally substituted 3-(imidazol-4-yl)propyl, an optionally substituted 3- (imidazol-l-yl)propyl, an optionally substituted 2-(morpholin-4-yl)ethyl, an optionally substituted 2-(4-pyrazolyl)ethyl, an optionally substituted
- R 2 2-(imidazol-4-yl)ethyl.
- R 3 is an optionally substituted aryl group or an optionally substituted Cj- C 4 aralkyl group.
- R 3 is an optionally substituted an optionally substituted 2- cyclohexylethyl, an optionally substituted 2-cyclopentylethyl, or an optionally substituted C 3 -C 8 secondary or tertiary alkyl group.
- R 3 is an optionally substituted phenyl, an optionally substituted phenyl- C ⁇ -C 4 -alkyl, an optionally substituted diphenyl-C ⁇ -C 4 -alkyl, an optionally substituted pyrazolyl, an optionally substituted pyrazolyl-C ⁇ -C 4 -alkyl, an optionally substituted indolyl, an optionally substituted indolyl-C ⁇ -C - alkyl, thienylphenyl, thienylphenyl-C ⁇ -C 4 -alkyl, furanylphenyl, furanylphenyl-C ⁇ -C 4 -alkyl, an optionally substituted fluorenyl, an optionally substituted fluorenyl-C ⁇ -C 4 -alkyl, an optionally substituted naphthyl, an optionally substituted naphthyl-C ⁇ -C 4 -alkyl, an optionally substituted quinoxalinyl,
- Ring A is substituted or unsubstituted;
- R 7 is an optionally substituted phenyl, optionally substituted furanyl, optionally substituted thienyl or optionally substituted pyridyl group;
- n is an integer from 1-4; and
- X is a bond, CH 2 , OCH 2 , CH 2 OC(O), CO, OC(O), C(O)O, O, S, SO or SO 2 .
- suitable substituents for Ring A and the aryl groups represented by R 7 are provided in section above describing suitable aryl group substituents.
- R 3 is represented by Formula (II), wherein Ring A is substituted or unsubstituted; R 7 is an optionally substituted phenyl group; n is 1; and X is CO.
- R 3 is represented by Formula (II), Ring A is unsubstituted R 7 is an optionally substituted phenyl group; n is 1; and X is CO. More preferably, R is a phenyl group. 1) R 4 is an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted C ⁇ -C aralkyl group or an optionally substituted C ⁇ -C 4 cycloalkylalkyl group.
- R 4 is an optionally substituted phenyl group, an optionally substituted phenyl-C ⁇ -C 4 -alkyl group, an optionally substituted diphenyl-C ⁇ -C 4 -alkyl group, an optionally substituted C 3 -C 8 -cycloalkyl-C ⁇ -C 4 -alkyl group or an optionally substituted di-(C -C 8 -cycloalkyl)-C ⁇ -C 4 -alkyl group, n) R 4 is an optionally substituted benzyl, an optionally substituted diphenylmethyl, an optionally substituted 2-phenylethyl, an optionally substituted 1,2-diphenylethyl, an optionally substituted 2,2-diphenylethyl or an optionally substituted 3,3-diphenylpropyl.
- R 4 Preferred substituents for these values of R 4 include C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, halogen, CN, - C 4 -alkylthiol, C ⁇ -C 4 -haloalkyl and phenoxy.
- the compound of Formula (I) is characterized by one or more of Features a), f) and 1), and preferably all of Features a), f) and 1).
- the compound of Formula (I) is characterized by one or more of Features b), h) and m), and preferably all of
- the compound of Formula (I) is additionally characterized by Feature d).
- the compound of Formula (I) is characterized by one or more of Features b), d), i) and m), and preferably all of Features b), d), i) and m).
- Feature m) is replaced by Feature n).
- Feature m) is replaced by Feature n) and Feature i) is replaced by Feature j).
- the compound of Formula (I) is characterized by one or more of Features b), d), k) and m), and preferably all of Features b), d), k) and m).
- the method of the present invention is carried out with the compound of Formula (III) in place of the compound of Formula (I):
- R ⁇ is -H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;
- R ⁇ 2 is alkyl substituted with NRi 5 R] 6 , a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;
- R ⁇ is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl; and each R] 4 is independently, -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;
- Ri 5 and R ⁇ 6 are independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl or unsubstituted aralkyl or R 15 and R ⁇ 6 together with the nitrogen to which they are attached are a heterocycloalkyl.
- EXEMPLLFICATION Suppression of Chronic Transplant Rejection Using Compound 1 in a First Mouse Model
- the ability of Compound 1 to inhibit chronic transplant rejection in a mouse model was tested. Specifically, hearts from donor B6.C-H2 m12 mice were transplanted into C57/BL6 recipient mice (MHC II mismatch) using standard protocol described in Hancock, W.W., et al. Proc.Natl. Acad. Sci. USA 93: 13967 (1996) and Yuan et al, Transplantation 73. 1736, the entire teachings of which are incorporated herein by reference. Following surgery, the mice were divided into the following treatment groups with seven mice each:
- Group I was a control group that was untreated.
- Group II was treated with Compound 1 at a dose of 75 mg/kg/day subcutaneously for fourteen days following surgery.
- Example 2 Suppression of Chronic Transplant Rejection Using Compound 1 in a Second Mouse Model The ability of compound 1 to inhibit chronic transplant rejection was tested in a mouse heterotypic allogeneic heart transplant model in which acute allograft rejection was prevented with CD 154 blockade as previously described (Hancock, W. W. et al. 1996. Proc. Nat/. Acad. Sci. USA.
- this model consists of fully mismatched cardiac allografts (C57/BL 6 donor with Balb/C recipient). Acute rejection occurred in all transplant recipients within 10 days post surgery without treatment, while treatment with Compound 1 alone resulted in a statistically significant extension in transplant survival to about 20 days. A third group in which acute rejection is blocked by administering a single 250 ⁇ g dose of anti-CD154 (anti-CD40 ligand) monoclonal antibody was established, and acute rejection (as evidenced by cessation of contraction of the transplanted heart) occurred in approximately 50% of recipient animals.
- anti-CD154 anti-CD40 ligand
- anti-CD 154 offers certain similarities to the human transplant clinical condition in that acute rejection is managed (in this case with the anti-CD 154 monoclonal antibody) so that chronic rejection pathology can be observed.
- the addition of Compound 1 (75 mg/kg daily, subcutaneous for 14 days post surgery) to a second group of animals that had received anti-CD 154 (to block acute rejection given as a single dose at immediately following surgery) resulted in a striking lack of acute rejection in 100% of transplant recipient animals for more than 100 days post surgery.
- Histological evaluation of the transplanted hearts for all three indicators of chronic graft rejection described above revealed a dramatic inhibition of all indicators of chronic rejection of the transplant. Histopathological scores for these hearts are also shown in Figure 2. Comparison of the scores in Figure 2 show that animals treated with Compound 1 had a dramatic decrease in chronic rejection compared with animals that were not treated with Compound 1.
- mice The ability of Compound 1 to inhibit transplant rejection in a mouse model was tested. Specifically, the heart from C57/BL6 mice was transplanted into Balb/c recipient mice (total MHC mismatch) using standard protocol described in Hancock, W.W., et al. "Costimulatory function and expression of CD40 ligand, CD80 and CD86 in vascularized murine cardiac allograft rejection" Proc.Natl. Acad. Sci. USA 93: 13967 (1996). Following surgery, the mice were divided into the following treatment groups :
- Group I is a control group that was untreated.
- Group II was treated with Compound 1 at a dose of 75 mg/kg/day subcutaneously for fourteen days following surgery.
- mice receiving no treatment reproducibly experienced rejection of their transplanted hearts after only ten days.
- Mice receiving Compound 1 alone showed a statistically significant delay (two to three weeks) (p ⁇ 0.001) in the onset of rejection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a method of inhibiting acute and chronic tissue transplant rejection in a subject with a tissue transplant. The method comprises the step of administering to the subject an effective amount of a compound represented by Formula (I): The values of the variables in Formula (I) are described herein.
Description
USE OF DIAMIDE DERIVATIVES FOR INHIBITING CHRONIC TISSUE TRANSPLANT REJECTION
RELATED APPLICATIONS PARAGRAPH
This Application claims the benefit of U.S. Provisional Application No. 60/428,332, filed November 21, 2002, the entire teachings of which are incorporated herein by reference.
BACKGROUND OF THE INNENTION
There have been improvements in the management of acute transplant rejection over the last thirty years as seen in the increased survival of transplants during the first year following the procedure. However, the half-life for long term organ survival has not improved and only about 50% of the transplants are functional at ten years. Chronic transplant rejection, as opposed to acute transplant rejection, is the cause for the majority of transplant failures. Acute transplant rejection occurs as a result of the immune system of the transplant recipient attacking the transplanted tissue. Acute rejection is rapid, generally occurs within hours to weeks after transplant of the tissue and can typically be suppressed with the use of immunosuppressive drugs such as cyclosporin A. Whereas acute rejection is suppressed with immunosuppressive protocols, treatment for chronic rejection is less well defined. Acute rejection and chronic rejection have significantly different characteristics as immune responses. For example, chronic rejection occurs over time, typically several months to years after engraftment, even in the presence of successful immunosuppression. It involves multiple factors and processes of the host and is usually the result of a prolonged process of wound healing the host undergoes post-transplant. Therefore, chronic rejection is not totally immuno logical in origin and additional causes(s) are not fully understood. They may include ischemic insult, denervation of the transplanted tissue, hyperlipidemia and hypertension associated with immunosuppressive drugs. For most organs, the most definitive way of showing that rejection is occurring is by biopsy of that organ. For practical reasons, however, biopsies are
not always done and are particularly less practical when chronic rejection is suspected. Chronic rejection of a transplant organ is generally characterized as failure of the organ after it has begun to perform its function in the recipient or host. Thus, chronic rejection is commonly monitored by a decrease in organ function which, if unarrested, results in failure of the organ, infection, and necrosis of organ tissue. Chronic rejection is identified, commonly too late for treatment that can save the transplant, by pathogenic fϊbrosis, which is characterized by extensive deposition of the extracellular matrix proteins: collagen, fibronectin, and elastin, and by emergence of cells with the myofϊbroblast phenotype. Fibrosis becomes a telltale characteristic of chronic rejection where fibrogenesis is observed to damage organ microstructures or to block passages that need to remain open for organ function.
The chronic rejection process is not inhibited by any known therapeutic regimen at this time. Moreover, as noted above, it is sometimes difficult to detect and treat in a time frame that will save the transplant. Thus, additional improvements in the long-term survival of organ transplant patients are dependent on the development of new techniques for managing chronic transplant rejection.
SUMMARY OF THE INNENTION
A new class of compounds that is effective in inhibiting chronic transplant rejection has now been discovered and is disclosed herein. In one example, the histopatho logical evidence of chronic rejection was inhibited in two mouse models by Compound 1, shown below. In the first model, chronic rejection of fully MHC class II mismatched transplanted hearts in recipient mice at eight weeks post surgery was inhibited by treatment with 75 mg/kg/day of
Compound 1
Compound 1 alone during the two weeks following surgery. In the second model, chronic rejection of fully MHC class II mismatched transplanted hearts in recipient mice at 120 days post surgery was inhibited when treatment with 75 mg/kg/day of Compound 1 during the two weeks following surgery was combined with a single administration of 250 μg of anti-CD 154 monoclonal antibody immediately following transplant surgery. Treatment with anti-CD 154 monoclonal antibody alone suppresses acute rejection, but is ineffective in preventing chronic rejection of transplanted tissue. Based on these results, methods of treating chronic transplant rejection are disclosed herein.
The present invention is a method of inhibiting tissue transplant rejection in a subject with a tissue transplant. The method is effective against both acute and chronic rejection of transplanted tissue, but is particularly advantageous in inhibiting chronic transplant rejection. The method comprises the step of administering to the subject an effective amount of a compound represented by Formula (I):
Ri is a substituted or unsubstituted aryl group or a substituted or unsubstituted alkyl group.
R2 is an optionally substituted aralkyl group or an alkyl group substituted with -NR5R6. R3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group.
P a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group.
R5 and R$ are independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group or R5 and R taken together with the nitrogen to which they are attached are a non-aromatic heterocyclic group.
The disclosed method can be advantageously used to treat chronic rejection of transplanted tissue, a condition for which heretofore effective treatments were unavailable. Additionally, acute rejection of transplanted tissue can also be inhibited with the disclosed method.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph showing inhibition of chronic vasculopathy in transplanted hearts in a model consisting of only MHC class II mismatched mice at eight weeks following heart transplant. The graph compares inhibition of chronic vasculopathy in a group of mice treated with 75 mg/kg of Compound 1 subcutaneously for fourteen days after heart transplant surgery with an untreated control group. The scores shown in the graph range from zero to five to indicate the severity of chronic rejection accelerated atherosclerosis, with zero being normal blood vessel and five being fully occluded.
Figure 2 is a graph showing inhibition of chronic vasculopathy in transplanted hearts in a model consisting of only fully mismatched mice greater than 100 days following heart transplant. The graph compares inhibition of chronic vasculopathy in a group of mice treated with a single 250 μm dose of anti-CD 154 monoclonal antibody immediately following heart transplant surgery with a group of mice treated with a single 250 μm dose of anti-CD154 immediately following heart transplant surgery and 75 mg/kg of Compound 1 subcutaneously for fourteen days
after heart transplant surgery. The scores shown in the graph range from zero to five to indicate the severity of chronic rejection accelerated atherosclerosis, with zero being normal blood vessel and five being fully occluded.
DETAILED DESCRIPTION OF THE INNENTION
Disclosed herein is a method of treating (preventing, inhibiting or suppressing) rejection of transplanted tissue in a recipient subject. The method is particularly effective in treating (preventing, inhibiting or suppressing) chronic transplant rejection. Optionally, the disclosed method can also be used to treat (prevent, inhibit or suppress) acute transplant rejection.
"Acute transplant rejection" is the rejection by the immune system of a tissue transplant recipient when the transplanted tissue is immunologically foreign. Acute rejection is characterized by infiltration of the transplanted tissue by immune cells of the recipient, which carry out their effector function and destroy the transplanted tissue. The onset of acute rejection is rapid and generally occurs in humans within a few weeks after transplant surgery. Generally, acute rejection can be inhibited or suppressed with immunosuppressive drugs such as rapamycin, cyclosporin A, anti-CD40L monoclonal antibody and the like. "Chronic transplant rejection" generally occurs in humans within several months to years after engraftment, even in the presence of successful immunosuppression of acute rejection. Fibrosis is a common factor in chronic rejection of all types of organ transplants. Chronic rejection can typically be described by a range of specific disorders that are characteristic of the particular organ. For example, in lung transplants, such disorders include fibroproliferative destruction of the airway (bronchiolitis obliterans); in heart transplants or transplants of cardiac tissue, such as valve replacements, such disorders include fibrotic atherosclerosis; in kidney transplants, such disorders include, obstructive nephropathy, nephrosclerorsis, tubulointerstitial nephropathy; and in liver transplants, such disorders include disappearing bile duct syndrome. Chronic rejection can also be characterized by ischemic insult, denervation of the
transplanted tissue, hyperlipidemia and hypertension associated with immunosuppressive drugs.
The term "transplant rejection" encompasses both acute and chrome transplant rejection. As described above, the disclosed methods can be advantageously used to inhibit or suppress transplant rejection, preferably chronic rejection, in a mammal with an organ or tissue transplant. The most common type of transplant is an allograft, which is a graft between members of the same species.
In one alternative, the transplanted tissue or organ is bio-engineered, e.g., when the transplanted tissue or organ is grown from a stem cell or other type of precursor cell(s). Bio-engineered tissues or organs can be grown outside of the body and transplanted directly into the host. Alternatively, the precursor cells or immature organ or tissue is transplanted into the host to grow and mature.
The disclosed method can also be used to treat tranplant rejection when the tranplanted organ or tissue is a xenograft, i.e., the donor is a member of a species different than the recipient. Xenografts are advantageously used with a bio- engineered tissue or organ, which, instead of being transplanted directly into the recipient in need of the tissue or organ, can be transplanted into a surrogate host such as non-human mammal until a suitable human recipient in need of the bio- engineered tissue or organ is identified. Alternatively, the tissue or organ can be transplanted into the surrogate to allow the bio-engineered tissue or organ to mature. Use of surrogate hosts may be preferred in instances where further development of the tissue or organ is required before transplantation into a human recipient. In another alternative, a xenograft is used when a suitable allograft donor is unavailable. When transplanting into a different a species, it is desirable to select a host such that the size of the organs in the host and donor are similar. In addition, the host is selected to minimize transmission of communicable diseases.
The term "aryl group", (e.g., the aryl groups represented by Ri, R3 and R4) used alone or as part of a larger moiety such as "aralkyl" (e.g., the aralkyl group represented by R2), refers to carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, isoimidazolyl, thienyl, furanyl, pyridyl, pyrimidyl, pyranyl, pyrazolyl, pyrrolyl, pyrazinyl, thiazolyl,
isothiazolyl, oxazolyl, isooxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, and tetrazolyl.
The term "aryl group", used alone or as part of a larger moiety such as "aralkyl", also includes fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazolyl, quinoxalinyl, quinazolinyl, benzoisothiazolyl, benzooxazolyl, benzoisooxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl and isoindolyl.
The term "aryl group", used alone or as part of a larger moiety such as "aralkyl", also includes carbocylic aromatic rings or heteroaryl aromatic rings fused to a cycloalkyl group or an non-aromatic heterocyclic group. Examples include indanyl, tetrahydronaphthyl and fluorenyl.
The term "alkyl group" (e.g., the alkyl groups represented by R1-R-5), used alone or as part of a larger moiety such as "aralkyl" (e.g., the aralkyl group represented by R2) or "cycloalkylalkyl", is a straight, branched or cyclic non- aromatic hydrocarbon which is completely saturated. Typically, a straight or branched alkyl group has from 1 to about 10 carbon atoms, preferably from 1 to about 4, and a cyclic aliphatic group has from 3 to about 10 carbon atoms, preferably from 3 to about 8. Examples of suitable straight or branched alkyl group include methyl, ethyl, n-propyl, tsø-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl; and examples of suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. A C1-C10 straight or branched alkyl group or a C3-C8 cyclic alkyl group are also referred to as a "lower alkyl" group.
An "aralkyl group" is an alkyl group substituted with one or more aryl groups. A "substituted aralkyl group" can have one or more substituents on the alkyl part of the aralkyl group and/or on the aryl part of the aralkyl group. Suitable aralkyl group substituents are described below in the section providing examples of aryl group substituents and alkyl group substituents.
A "heteroaralkyl group" is an alkyl group substituted with one or more heteroaryl groups. A "substituted heteroaralkyl group" can have one or more substituents on the alkyl part of the heteroaralkyl group and/or on the heteroaryl part
of the heteroaralkyl group. Suitable heteroaralkyl group substituents are described below in the section providing examples of aryl group substituents and alkyl group substituents.
A "cycloalkylalkyl group" is an alkyl group substituted with one or more cycloalkyl groups. A "substituted cycloalkylalkyl group" can have one or more substituents on the alkyl part or cycloalkylalkyl part of the cycloalkylalkyl group. Suitable cycloalkylalkyl group substituents are described below in the section providing examples of alkyl group substituents.
A "heterocycloalkylalkyl group" is an alkyl group substituted with one or more non-aromatic heterocyclic groups. A "substituted heterocycloalkylalkyl group" can have one or more substituents on the alkyl part or non-aromatic heterocyclic part of the heterocycloalkylalkyl group. Suitable heterocycloalkylalkyl group substituents are described below in the section providing examples of alkyl group substituents and non-aromatic heterocyclic group substitutents. The term "non-aromatic heterocyclic ring" (e.g., non-aromatic heterocyclic groups represented by -NR5Rό) refers to non-aromatic ring systems typically having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S. Examples of non-aromatic heterocyclic rings include 3-lH-benzimidazol-2-one, 3- tefrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [l,3]-dioxalanyl, [l,3]-dithiolanyl, [l,3]-dioxanyl, 2-tetrahydrothiophenyl, 3- tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2- thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2- pyrrolidinyl, 3-pyrorolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2- piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1-pthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl, and benzothianyl.
Suitable substituents for an alkyl group, for a carbon atom on an aryl group or a non-aromatic heterocyclic group are those which do not substantially interfere with the ability of the compound to inhibit transplant rejection. Examples of suitable substituents for a carbon atom of an aryl, alkyl or a carbon atom of a non-aromatic
heterocyclic group include -OH, halogen (-Br, -CI, -I and -F), R, -CH2R, -OCH2R, -CH2OC(O)R, -OR, -O-COR, -COR, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR, - N(R)2, -COOR, -CHO, -CONH2, -CONHR, -CON(R)2, -NHCOR, -NRCOR, -NHCONH2, -NHCONRH, -NHCON(R)2, -NRCONH2, -NRCONRH, -NRCON(R)2, -C(=NH)-NH2, -C(=NH)-NHR, -C(=NH)-N(R)2, -C(=NR)-NH2, -C(=NR)-NHR, -C(=NR)-N(R)2, -NH-C(=NH)-NH2, -NH-C(=NH)-NHR, -NH-C(=NH)-N(R)2, -NH-C(=NR)-NH2, -NH-C(=NR)-NHR, -NH-C(=NR)-N(R)2, -NRH-C(=NH)-NH2, -NR-C(=NH)-NHR, -NR-C(=NH)-N(R)2, -NR-C(=NR)-NH2, -NR-C(=NR)-NHR, -NR-C(=NR)-N(R)2, -SO2NH2, -SO2NHR, -SO2NR2, -SH, -SOkR (k is 0, 1 or 2) and -NH-C(=NH)-NH2. Each R is independently an alkyl, substituted alkyl, benzyl, substituted benzyl, aryl or substituted aryl group. Preferably, R is an alkyl, benzylic or aryl group. In addition, -N(R)2, taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group, such as pyrollidinyl, piperidinyl, morpholinyl and thiomorpholinyl. Examples of substituents on the alkyl, aryl or benzyl group represented by R include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl. A substituted aryl, alkyl and non- aromatic heterocyclic group can have more than one substitutent. Suitable substitutents on a substitutable nitrogen of a non-aromatic heterocyclic group or heteroaryl group include -R', -N(R')2, -C(O)R', -CO2 R , -C(O)C(O)R', -C(O)CH2 C(O)R', -SO2R', -SO2 N(R')2, -C(=S)N(R')2, -C(=NH)- N(R')2, and -NR' SO2R'; wherein R' is hydrogen, an alkyl group, a substituted alkyl group, phenyl (Ph), substituted Ph, -O(Ph), substituted -O(Ph), CH2(Ph), or an unsubstituted heteroaryl or non-aromatic heterocyclic ring. Examples of substituents on the aliphatic group or the phenyl ring represented by R' include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl. Additionally, pharmaceutically acceptable salts of the disclosed compounds can be used in the disclosed methods. For example, an acid salt of a compound
containing an amine or other basic group can be obtained, by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base. Such a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, 2- hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, N-benzyl-β-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.
An "effective amount" according to the present invention of a compound of Formula (I) is the quantity which, when administered to a transplant recipient, inhibits or suppresses transplant rejection, i.e., delays the onset of and/or reduces the severity of one or more of the symptoms associated with transplant rejection, and preferably with chronic transplant rejection. The amount of the disclosed compound to be administered to a transplant recipient will depend on the type of transplant, the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective amounts of the disclosed compounds typically range between about 0.01 mg/kg per day and about 100 mg/kg per day, and preferably between 0.1 mg/kg per day and about 10 mg/kg/day.
A "subject" is a mammal, preferably a human, but can also be an animal who has received a tissue transplant and is in need of treatment to inhibit transplant rejection, and preferably chronic transplant rejection. Examples of recipient animals in need of such treatment include, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
The use of the disclosed compounds to inhibit transplant rejection, e.g., chronic transplant rejection, is not limited to any particular organ or tissue type. The disclosed treatment is effective, but not limited to, inhibiting rejection of transplanted heart, kidney, lung, liver, pancreas, pancreatic islets, brain tissue, stomach, large intestine, small intestine, cornea, skin, trachea, bone, bone marrow, muscle, bladder or parts thereof.
The compounds described herein, and the pharmaceutically acceptable salts thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995).
For oral administration, the disclosed compounds or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like. The tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch or alginic acid; a lubricant such as magnesium stearate; and/or a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
Narious other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
For parental administration of the disclosed compounds, or salts thereof, can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Suitable formulations of this type include biocompatible and biodegradable polymeric hydrogel formulations using crosslinked or water insoluble polysaccharide formulations. Also included are polymerizable polyethylene oxide formulations. Formulations of this type are disclosed in U.S. Patent Νos. 5,410,016, 4,713,448, 4,636,524, 6,083,524, 5,785,993, 4,937,270 and 5,017,229, the entire teachings of which are incorporated herein by reference. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection. Preferably, they are implanted in the microenvironment of the transplanted organ or tissue. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials, for example, as an emulsion in an acceptable oil, or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
Preferably disclosed compounds or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal. The unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IN bag, a tablet, or a vial. The quantity of active ingredient (viz., a compound of Formula I or salts thereof) in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved.
It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
The compound used in the method of the present invention can be advantageously co-administered with immunosuppressive drugs. Examples include corticosteroids, cyclosporin A, rapamycin and FK506 or antibody therapies such as anti T-cell antibodies. It is particularly useful to co-administer a compound represented by Formula (I) with rapamycin or anti-CD40L monoclonal antibody.
Compounds of the present invention can be prepared according to procedures disclosed in WO 01/87849, the entire teachings of which are incorporated herein by reference.
In a preferred embodiment, the variables for the compound represented by Formula (I) are as provided above, provided that the compound is characterized by one or more of the following features: a) Ri is an optionally substituted aryl group or an optionally substituted Ci- C4 aralkyl group. b) Ri is an optionally substituted phenyl group or an optionally substituted phenyl-Cι-C alkyl group. Preferred substituents for these values of Ri include Cι-C alkyl, Cι-C4 alkoxy, halogen, CN, Cι-C4-alkylthiol, -C4- haloalkyl and phenoxy. c) R2 is an optionally substituted heteroaralkyl group or an alkyl group substituted with -NR5R6. d) R2 is an optionally substituted imadazolyl-Cι-C4-alkyl group or a Cι-C alkyl group substituted with -NRsRό. e) R2 is an optionally substituted 2-(imidazol-4-yl)ethyl, an optionally substituted 3-(imidazol-4-yl)propyl, an optionally substituted 3- (imidazol-l-yl)propyl, an optionally substituted 2-(morpholin-4-yl)ethyl, an optionally substituted 2-(4-pyrazolyl)ethyl, an optionally substituted
2-NN-dimethylaminoethyl or an optionally substituted 3-NN- dimethylaminopropyl. Preferably, R22-(imidazol-4-yl)ethyl.
f) R3 is an optionally substituted aryl group or an optionally substituted Cj- C4 aralkyl group. g) R3 is an optionally substituted an optionally substituted 2- cyclohexylethyl, an optionally substituted 2-cyclopentylethyl, or an optionally substituted C3-C8 secondary or tertiary alkyl group. h) R3 is an optionally substituted phenyl, an optionally substituted phenyl- Cι-C4-alkyl, an optionally substituted diphenyl-Cι-C4-alkyl, an optionally substituted pyrazolyl, an optionally substituted pyrazolyl-Cι-C4-alkyl, an optionally substituted indolyl, an optionally substituted indolyl-Cι-C - alkyl, thienylphenyl, thienylphenyl-Cι-C4-alkyl, furanylphenyl, furanylphenyl-Cι-C4-alkyl, an optionally substituted fluorenyl, an optionally substituted fluorenyl-Cι-C4-alkyl, an optionally substituted naphthyl, an optionally substituted naphthyl-Cι-C4-alkyl, an optionally substituted quinoxalinyl, an optionally substituted quinoxalinyl-Cι-C4- alkyl, an optionally substituted quinazolinyl, an optionally substituted quinazolinyl-Cι-C4-alkyl, an optionally substituted pyrolyl, an optionally substituted pyrolyl-Cι-C -alkyl, an optionally substituted thienyl, an optionally substituted thienyl-Cι-C -alkyl, an optionally substituted furanyl, an optionally substituted furanyl-Ci- -alkyl, an optionally substituted pyridyl or an optionally substituted-Cι-C4 pyridyl. i) R3 is represented by Formula (II):
Ring A is substituted or unsubstituted; R7 is an optionally substituted phenyl, optionally substituted furanyl, optionally substituted thienyl or optionally substituted pyridyl group; n is an integer from 1-4; and X is a bond, CH2, OCH2, CH2OC(O), CO, OC(O), C(O)O, O, S, SO or SO2. Examples of suitable substituents for Ring A and the aryl groups represented by R7 are provided in section above describing suitable aryl group substituents.
j) R3 is represented by Formula (II), wherein Ring A is substituted or unsubstituted; R7 is an optionally substituted phenyl group; n is 1; and X is CO. k) R3 is represented by Formula (II), Ring A is unsubstituted R7 is an optionally substituted phenyl group; n is 1; and X is CO. More preferably, R is a phenyl group. 1) R4 is an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted Cι-C aralkyl group or an optionally substituted Cι-C4 cycloalkylalkyl group. m) R4 is an optionally substituted phenyl group, an optionally substituted phenyl-Cι-C4-alkyl group, an optionally substituted diphenyl-Cι-C4-alkyl group, an optionally substituted C3-C8-cycloalkyl-Cι-C4-alkyl group or an optionally substituted di-(C -C8-cycloalkyl)-Cι-C4-alkyl group, n) R4 is an optionally substituted benzyl, an optionally substituted diphenylmethyl, an optionally substituted 2-phenylethyl, an optionally substituted 1,2-diphenylethyl, an optionally substituted 2,2-diphenylethyl or an optionally substituted 3,3-diphenylpropyl. Preferred substituents for these values of R4 include Cι-C4 alkyl, Cι-C4 alkoxy, halogen, CN, - C4-alkylthiol, Cι-C4-haloalkyl and phenoxy.
In another preferred embodiment, the compound of Formula (I) is characterized by one or more of Features a), f) and 1), and preferably all of Features a), f) and 1).
In another preferred embodiment, the compound of Formula (I) is characterized by one or more of Features b), h) and m), and preferably all of
Features b), h) and m). More preferably, the compound of Formula (I) is additionally characterized by Feature d).
In another preferred embodiment, the compound of Formula (I) is characterized by one or more of Features b), d), i) and m), and preferably all of Features b), d), i) and m). Alternatively, Feature m) is replaced by Feature n). In another alternative, Feature m) is replaced by Feature n) and Feature i) is replaced by Feature j).
In another preferred embodiment, the compound of Formula (I) is characterized by one or more of Features b), d), k) and m), and preferably all of Features b), d), k) and m).
In yet another embodiment, the method of the present invention is carried out with the compound of Formula (III) in place of the compound of Formula (I):
Rπ is -H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;
Rι2 is alkyl substituted with NRi5R]6, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;
Rι is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl; and each R]4 is independently, -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;
Ri5 and Rι6 are independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl or unsubstituted aralkyl or R15 and Rι6 together with the nitrogen to which they are attached are a heterocycloalkyl.
The invention is illustrated by the following examples, which are not intended to be limiting in any way.
EXEMPLLFICATION Example 1 Suppression of Chronic Transplant Rejection Using Compound 1 in a First Mouse Model The ability of Compound 1 to inhibit chronic transplant rejection in a mouse model was tested. Specifically, hearts from donor B6.C-H2 m12 mice were transplanted into C57/BL6 recipient mice (MHC II mismatch) using standard protocol described in Hancock, W.W., et al. Proc.Natl. Acad. Sci. USA 93: 13967 (1996) and Yuan et al, Transplantation 73. 1736, the entire teachings of which are incorporated herein by reference. Following surgery, the mice were divided into the following treatment groups with seven mice each:
Group I was a control group that was untreated. Group II was treated with Compound 1 at a dose of 75 mg/kg/day subcutaneously for fourteen days following surgery.
At eight weeks following transplant surgery, the mice were sacrificed and evaluated for chronic rejection accelerated atherosclerosis. Briefly, transplanted hearts were fixed in formalin, embedded in paraffin and sectioned coronally. The sections were scanned for arterial blood vessels, which were subjected to a histopathological score. The histopathological scores (range 0-5 indicating severity of chronic rejection accelerated atherosclerosis, with 0 being normal blood vessel and 5 being fully occluded) are shown in Figure 1. Compound 1 significantly (p = 0.0002) prevented histological evidence of chronic rejection when data was averaged for all animals in the study. The effect was even more significant when the score for each animal is examined individually, e.g., 4/7 animals were free of vasculopathy, while three treated animals showed full involvement. The three animals in the treatment group showing the higher scores were the last to be treated, and they may have suffered from diminished exposure to the compound, which was observed to have precipitated from solution during handling and dilution in the syringe when they were being treated. It is likely that increased bioavailability resulting from improved compound formulation will result in more complete protection from chronic rejection vasculopathy.
Example 2 Suppression of Chronic Transplant Rejection Using Compound 1 in a Second Mouse Model The ability of compound 1 to inhibit chronic transplant rejection was tested in a mouse heterotypic allogeneic heart transplant model in which acute allograft rejection was prevented with CD 154 blockade as previously described (Hancock, W. W. et al. 1996. Proc. Nat/. Acad. Sci. USA. 93:13967; and Yuan et al., Transplantation 73:1736). Briefly, this model consists of fully mismatched cardiac allografts (C57/BL 6 donor with Balb/C recipient). Acute rejection occurred in all transplant recipients within 10 days post surgery without treatment, while treatment with Compound 1 alone resulted in a statistically significant extension in transplant survival to about 20 days. A third group in which acute rejection is blocked by administering a single 250 μg dose of anti-CD154 (anti-CD40 ligand) monoclonal antibody was established, and acute rejection (as evidenced by cessation of contraction of the transplanted heart) occurred in approximately 50% of recipient animals. Importantly, the remaining 50 % of recipients that did not demonstrate acute rejection retained a functional graft for an extended period of time (greater than 100 days). Histological examination of the transplanted hearts in this treatment group at 100 days post surgery displays 3 major hallmarks of the chronic rejection process. These include profound athlerosclerotic blockages of heart arteries, cellular inflammation (immune cell infiltration into the heart muscle itself), and fibrotic scarring of the cardiac parenchyma. The hearts were subjected to a histopathological score. The histopathological scores (range 0-5 indicating severity of chronic rejection accelerated atherosclerosis, with 0 being normal blood vessel and 5 being fully occluded) are shown in Figure 2. Thus the addition of anti-CD 154 to this model offers certain similarities to the human transplant clinical condition in that acute rejection is managed (in this case with the anti-CD 154 monoclonal antibody) so that chronic rejection pathology can be observed. The addition of Compound 1 (75 mg/kg daily, subcutaneous for 14 days post surgery) to a second group of animals that had received anti-CD 154 (to block acute rejection given as a single dose at immediately following surgery) resulted in a striking lack of acute rejection in 100% of transplant recipient animals for more than 100 days post surgery. Histological evaluation of the transplanted hearts for all three indicators of
chronic graft rejection described above revealed a dramatic inhibition of all indicators of chronic rejection of the transplant. Histopathological scores for these hearts are also shown in Figure 2. Comparison of the scores in Figure 2 show that animals treated with Compound 1 had a dramatic decrease in chronic rejection compared with animals that were not treated with Compound 1.
Example 3 Suppression of Transplant Rejection Using Compound 1
The ability of Compound 1 to inhibit transplant rejection in a mouse model was tested. Specifically, the heart from C57/BL6 mice was transplanted into Balb/c recipient mice (total MHC mismatch) using standard protocol described in Hancock, W.W., et al. "Costimulatory function and expression of CD40 ligand, CD80 and CD86 in vascularized murine cardiac allograft rejection" Proc.Natl. Acad. Sci. USA 93: 13967 (1996). Following surgery, the mice were divided into the following treatment groups :
Group I is a control group that was untreated.
Group II was treated with Compound 1 at a dose of 75 mg/kg/day subcutaneously for fourteen days following surgery.
Control mice receiving no treatment reproducibly experienced rejection of their transplanted hearts after only ten days. Mice receiving Compound 1 alone showed a statistically significant delay (two to three weeks) (p < 0.001) in the onset of rejection.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims
CLALMS
What is claimed is:
A method of inhibiting tissue transplant rejection in a subject with a tissue transplant, said method comprising the step of administering an effective amount of a compound represented by Formula (I):
or a physiological salt thereof, wherein:
Ri is a substituted or unsubstituted aryl group or a substituted or unsubstituted alkyl group;
R2 is an optionally substituted aralkyl group or an alkyl group substituted with -NRsRe;
R3 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
R-4 a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; and
R5 and Rό are independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group or R5 and Rό taken together with the nitrogen to which they are attached are a non- aromatic heterocyclic group.
A method of inhibiting chronic tissue transplant rejection in a subject with a tissue transplant, said method comprising the step of administering an effective amount of a compound represented by Formula (I):
or a physiological salt thereof, wherein:
Ri is a substituted or unsubstituted aryl group or a substituted or unsubstituted alkyl group;
R2 is an optionally substituted aralkyl group or an alkyl group substituted with -NR5R6;
R is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; t a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; and R and Re are independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group or R5 and Rό taken together with the nitrogen to which they are attached are a non- aromatic heterocyclic group.
3. The method of Claim 2 wherein R2 is an optionally substituted heteroaralkyl group or an alkyl group substituted with -NR5Re.
4. The method of Claim 3 wherein R^ is an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted C]-C4 aralkyl group or an optionally substituted Cj-C4 cycloalkylalkyl group.
5. The method of Claim 4 wherein R-t is an optionally substituted phenyl group, an optionally substituted phenyl-Cι-C4-alkyl group, an optionally substituted diphenyl-Cι-C4-alkyl group, an optionally substituted C3-C8-cycloalkyl-Cι- C4-alkyl group or an optionally substituted di-(C -C8-cycloalkyl)-Cι-C -alkyl group.
6. The method of Claim 5 wherein R is an optionally substituted benzyl, an optionally substituted diphenylmethyl, an optionally substituted 2- phenylethyl, an optionally substituted 1,2-diphenylethyl, an optionally substituted 2,2-diphenylethyl or an optionally substituted 3,3- diphenylpropyl.
7. The method of Claim 3 wherein R\ is an optionally substituted aryl group or an optionally substituted Cι-C aralkyl group.
8. The method of Claim 7 wherein Ri is an optionally substituted phenyl group or an optionally substituted phenyl-Cι-C4 alkyl group.
9. The method of Claim 3 wherein R3 is an optionally substituted aryl group or an optionally substituted Cι-C aralkyl group.
10. The method of Claim 9 wherein R3 is an optionally substituted phenyl, an optionally substituted phenyl-Cι-C4-alkyl, an optionally substituted diphenyl-Cι-C4-alkyl, an optionally substituted pyrazolyl, an optionally substituted pyrazolyl-Cι-C -alkyl, an optionally substituted indolyl, an optionally substituted indolyl-Cι-C -alkyl, thienylphenyl, thienylphenyl-Ci-
C4-alkyl, furanylphenyl, furanylphenyl-Cι-C4-alkyl, an optionally substituted fluorenyl, an optionally substituted fluorenyl-Cι-C4-alkyl, an optionally substituted naphthyl, an optionally substituted naphthyl-Cι-C4-alkyl, an optionally substituted quinoxalinyl, an optionally substituted quinoxalinyl- Cι-C -alkyl, an optionally substituted quinazolinyl, an optionally substituted quinazolinyl-Cι-C4-alkyl, an optionally substituted pyrolyl, an optionally substituted pyrolyl-Cι-C -alkyl, an optionally substituted thienyl, an optionally substituted thienyl-Cι-C -alkyl, an optionally substituted furanyl, an optionally substituted furanyl-Cι-C4-alkyl, an optionally substituted pyridyl or an optionally substituted-Cι-C4 pyridyl.
11. The method of Claim 10 wherein R3 is represented by the following structural formula:
wherein Ring A substituted or unsubstituted; R is an optionally substituted phenyl, optionally substituted furanyl, optionally substituted thienyl or optionally substituted pyridyl group; n is an integer from 1 -4; and X is a bond, CH2, OCH2, CH2OC(O), CO, OC(O), C(O)O, O, S, SO or SO2.
12. The method of Claim 3 wherein R3 is an optionally substituted an optionally substituted 2-cyclohexylethyl, an optionally substituted 2-cyclopentylethyl, or an optionally substituted C3-C8 secondary or tertiary alkyl group.
13. The method of Claim 3 wherein R2 is an optionally substituted 2-(imidazol- 4-yl)ethyl, an optionally substituted 3-(imidazol-4-yl)propyl, an optionally substituted 3-(imidazol-l-yl)propyl, an optionally substituted 2-(morpholin- 4-yl)ethyl, an optionally substituted 2-(4-pyrazolyl)ethyl, an optionally substituted 2-NN-dimethylaminoethyl or an optionally substituted 3-NN- dimethylaminopropyl.
14. The method of Claim 3 wherein: a) Ri is an optionally substituted aryl group or an optionally substituted - C4 aralkyl group; b) R3 is an optionally substituted aryl group or an optionally substituted Ci-
C aralkyl group; and c) R4 is an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted Cι-C aralkyl group or an optionally substituted Cι-C cycloalkylalkyl group.
15. The method of Claim 3 wherein: a) Ri is an optionally substituted phenyl group or an optionally substituted phenyl-Cι-C alkyl group; b) R3 a substituted or unsubstituted phenyl, phenyl-Cι-C -alkyl, diphenyl- Cι-C4-alkyl, pyrazolyl, pyrazolyl-Cι-C -alkyl, indolyl, indolyl-Cι-C - alkyl, thienylphenyl, thienylphenyl-Cι-C4-alkyl, furanylphenyl, furanylphenyl-Cι-C4-alkyl, fluorenyl, fluorenyl-Cι-C -alkyl, naphthyl,
naphthyl-Cι-C4-alkyl, quinoxalinyl, quinoxalinyl-Cι-C4-alkyl, an optionally substituted quinazolinyl, an optionally substituted quinazolinyl-Cι-C -alkyl, pyrolyl, ρyrolyl-Cι-C -alkyl, thienyl, thienyl- Cι-C4-alkyl, furanyl or furanyl-Cι-C4-alkyl; and c) R is an optionally substituted phenyl group, an optionally substituted phenyl-Cι-C4-alkyl group, an optionally substituted diphenyl-Cι-C4-alkyl group, an optionally substituted C3-C8-cycloalkyl-Cι-C4-alkyl group or an optionally substituted di-(C3-C8-cycloalkyl)-Cι-C4-alkyl group.
16. The method of Claim 15 wherein R2 is an optionally substituted imadazolyl- Cι-C4-alkyl group or a C.-C alkyl group substituted with -NRsRό.
17. The method of Claim 16 wherein R3 is represented by the following structural formula:
wherein Ring A substituted or unsubstituted; R7 is an optionally substituted phenyl, furanyl, thienyl or pyridyl group; n is an integer from 1-4; and X is a bond, CH2, OCH2, CH2OC(O), CO, OC(O), C(O)O, O, S, SO or SO2.
18. The method of Claim 17 wherein R-ι is 2,2-diphenylethyl, 2-phenylethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, benzyl, or 2- pyridylethyl, each optionally substituted with -OH, halogen, R, -CH2R, -OCH2R, -CH2OC(O)R, -OR, -O-COR, -COR, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR, -N(R)2, -COOR, -CHO, -CONH2, -CONHR, -CON(R)2,
-NHCOR, -NRCOR, -NHCONH2, -NHCONRH, -NHCON(R)2, -NRCONH2, -NRCONRH, -NRCON(R)2, -C(=NH)-NH2, -C(=NH)-NHR, -C(=NH)-N(R)2, -C(=NR)-NH2, -C(=NR)-NHR, -C(=NR)-N(R)2, - NH-C(=NH)-NH2, -NH-C(=NH)-NHR, -NH-C(=NH)-N(R)2, -NH-C(=NR)-
NH , -NH-C(=NR)-NHR, -NH-C(=NR)-N(R)2, -NRH-C(=NH)-NH2, -NR-C(=NH)-NHR, -NR-C(=NH)-N(R)2, -NR-C(=NR)-NH2, -NR-C(=NR)-NHR, -NR"C(=NR)-N(R)2, -SO2NH2, -SO2NHR, -SO2N(R)2, -SH or -SOkR; each R is independently Cι-C4 alkyl or phenyl optionally substituted with amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl; and k is zero, one or two.
19. The method of Claim 18 wherein Ri is a phenyl group or phenyl-Cι-C4 alkyl group each optionally substituted with R, -CH2R, -OCH2R, -CH2OC(O)R, - OH, halogen, -OR, -O-COR, -COR, -CN, -NO2, -COOH, -SO3H, -NH2, - NHR, -N(R)2, -COOR, -CHO, -CONH2, -CONHR, -CON(R)2, -NHCOR, -
NRCOR, -NHCONH2, -NHCONRH, -NHCON(R)2, -NRCONH2, -NRCONRH, -NRCON(R)2, -C(=NH)-NH2, -C(=NH)-NHR, -C(=NH)- N(R) , -C(=NR)-NH2, -C(=NR)-NHR, -C(=NR)-N(R)2, -NH-C(=NH)-NH2, -NH-C(=NH)-NHR, -NH-C(=NH)-N(R)2, -NH-C(=NR)-NH2, -NH-C(=NR)- NHR, -NH-C(=NR)-N(R)2, -NRH-C(=NH)-NH2, -NR-C(=NH)-NHR,
-NR-C(=NH)-N(R)2, -NR-C(=NR)-NH2, -NR-C(=NR)-NHR, -NR"C(=NR)- N(R)2, -SO2NH2, -SO2NHR, -SO2N(R)2, -SH or -SOkR.
20. The method of Claim 19 wherein Ri is a phenyl group or phenyl-Cι-C2 alkyl group, each optionally substituted with Cι-C4 alkyl, Cι-C4 alkoxy, halogen,
CN, C]-C -alkylthiol, Cι-C4-haloalkyl or phenoxy; R4 is 2,2-diphenylethyl, 2-phenylethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, benzyl, or 2-pyridylethyl, each optionally substituted with Cι-C4 alkyl, Cι-C4 alkoxy, halogen, CN, Cι-C4-alkylthiol, Cι-C4- haloalkyl or phenoxy; R is an optionally substituted phenyl group; n is 1 ; and X is CO.
21. The method of Claim 20 wherein Ring A is unsubstituted and R is a phenyl group optionally substituted with R, -CH2R, -OCH2R, -CH2OC(O)R, -OH, halogen, -OR, -O-COR, -COR, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR, - N(R)2, -COOR, -CHO, -CONH2, -CONHR, -CON(R)2, -NHCOR, -NRCOR, -NHCONH2, -NHCONRH, -NHCON(R)2, -NRCONH2, -NRCONRH,
-NRCON(R)2, -C(=NH)-NH2, -C(=NH)-NHR, -C(=NH)-N(R)2, -C(=NR)- NH2, -C(=NR)-NHR, -C(=NR)-N(R)2, -NH-C(=NH)-NH2, -NH-C(=NH)- NHR, -NH-C(=NH)-N(R)2, -NH-C(=NR)-NH2, -NH-C(=NR)-NHR, -NH-C(=NR)-N(R)2, -NRH-C(=NH)-NH2, -NR-C(=NH)-NHR, -NR-C(=NH)-N(R)2, -NR-C(=NR)-NH2, -NR-C(=NR)-NHR, -NR"C(=NR)-
N(R)2, -SO2NH2, -SO2NHR, -SO2N(R)2, -SH or -SOkR.
22. The method of Claim 21 wherein R7 is a phenyl group.
23. The method of Claim 22 wherein R2 is 2-(imidazol-4-yl)ethyl.
24. A method of inhibiting tissue transplant rejection in a subject with a tissue transplant, said method comprising the step of administering an effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.
25. A method of inhibiting chronic tissue transplant rejection in a subject with a tissue transplant, said method comprising the step of administering an effective amount of a compound represented by the following structural formula:
(II). or a pharmaceutically acceptable salt thereof.
26. A method of inhibiting tissue transplant rejection in a subject with a tissue transplant, said method comprising the step of administering an effective amount of a compound represented by the following structural formula:
or a physiologically acceptable salt thereof, wherein: Rii is -H, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;
R12 is alkyl substituted with NR15R16, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;
Rι3 is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl; and each Rι4 is independently, -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl;
R15 and Ri6 are independently selected from H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl or unsubstituted aralkyl or Rι3 and Rι4 together with the nitrogen to which they are attached are a heterocycloalkyl.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42833202P | 2002-11-21 | 2002-11-21 | |
| US428332P | 2002-11-21 | ||
| PCT/US2003/037318 WO2004047825A1 (en) | 2002-11-21 | 2003-11-21 | Use of diamide derivatives for inhibiting chronic tissue transplant rejection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10010574.1 Division-Into | 2010-09-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1567138A1 true EP1567138A1 (en) | 2005-08-31 |
| EP1567138B1 EP1567138B1 (en) | 2011-01-05 |
Family
ID=32393386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03783726A Expired - Lifetime EP1567138B1 (en) | 2002-11-21 | 2003-11-21 | Use of a diamide derivative for inhibiting chronic transplant rejection |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7687530B2 (en) |
| EP (1) | EP1567138B1 (en) |
| JP (2) | JP4928079B2 (en) |
| AT (1) | ATE493980T1 (en) |
| AU (1) | AU2003291134A1 (en) |
| DE (1) | DE60335652D1 (en) |
| ES (1) | ES2363914T3 (en) |
| PT (1) | PT1567138E (en) |
| WO (1) | WO2004047825A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781858C (en) * | 2000-05-12 | 2015-03-31 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
| ATE520400T1 (en) * | 2002-11-21 | 2011-09-15 | Genzyme Corp | COMBINATION OF A DIAMIDE DERIVATIVE AND IMMUNOSUPRESSIVES FOR SUPPRESSING TRANSPLANT REJECTION |
| AU2003291134A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Use of diamide derivatives for inhibiting chronic tissue transplant rejection |
| WO2005070086A2 (en) | 2004-01-21 | 2005-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| EP2604703B1 (en) | 2005-03-14 | 2017-02-01 | The Board of Trustees of the Leland Stanford Junior University | Methods for evaluating graft survival in a solid organ transplant recipient |
| USRE46843E1 (en) | 2005-03-14 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
| WO2010021696A1 (en) * | 2008-08-18 | 2010-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| ES2492498T3 (en) | 2009-01-15 | 2014-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarker panel for the diagnosis and prediction of graft rejection |
| EP2507630B1 (en) | 2009-12-02 | 2017-01-25 | The Board of Trustees of The Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
| WO2011119980A1 (en) | 2010-03-25 | 2011-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Protein and gene biomarkers for rejection of organ transplants |
| US8962261B2 (en) | 2011-04-06 | 2015-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Autoantibody biomarkers for IGA nephropathy |
| US20150038541A1 (en) * | 2012-03-19 | 2015-02-05 | Aposignal Bioscience Llc | Composition and methods for cell modulation |
| WO2017142879A1 (en) * | 2016-02-16 | 2017-08-24 | The Regents Of The University Of California | Methods for immune system modulation with microporous annealed particle gels |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US4944796A (en) * | 1988-11-14 | 1990-07-31 | Ici Americas Inc. | Certain 2-(disubstituted amino) acetanilide herbicides |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
| US6420374B1 (en) * | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
| US5861382A (en) * | 1992-05-01 | 1999-01-19 | Yeda Research And Development Co. Ltd. | Methods for regulation of active TNF-α |
| US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| CA2146647C (en) | 1992-10-08 | 2009-05-05 | Marc Feldmann | Treatment of autoimmune and inflammatory disorders |
| US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| JPH09510952A (en) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | Treatment of autoimmune and inflammatory diseases |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| DE4430127A1 (en) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Combination preparation containing cyclosporin A or FK506 and a xanthine derivative |
| DE4430128A1 (en) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Combination preparation with immunosuppressive, cardiovascular and cerebral effects |
| US5932737A (en) * | 1994-12-02 | 1999-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for treatment of no-mediated diseases |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| FR2730411B1 (en) * | 1995-02-14 | 1997-03-28 | Centre Nat Rech Scient | DRUG ASSOCIATION USEFUL FOR IN VIVO TRANSFECTION AND EXPRESSION OF EXOGENES |
| US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
| ATE259235T1 (en) | 1995-07-20 | 2004-02-15 | Cell Eng Ag | PREPARATION CONTAINING GLYCANS COMPLIANT WITH TRANSFERRIN GLYCANS AS AN ACTIVE PRINCIPLE FOR THE INDUCTION OF IMMUNOTOLERANCE AGAINST ANTIGENS |
| IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
| IL123431A (en) * | 1995-11-22 | 2001-05-20 | Darwin Discovery Ltd | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf) |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6211160B1 (en) * | 1996-09-06 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| WO1998024463A2 (en) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| WO1998039026A2 (en) | 1997-03-07 | 1998-09-11 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
| US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
| US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| US6229878B1 (en) * | 1998-01-21 | 2001-05-08 | Lucent Technologies, Inc. | Telephone answering method and apparatus |
| US6359061B1 (en) * | 1999-03-19 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Amide compound libraries |
| EP1165500A1 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| AU1590201A (en) | 1999-11-09 | 2001-06-06 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| CA2781858C (en) * | 2000-05-12 | 2015-03-31 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
| HUP0301932A3 (en) * | 2000-05-22 | 2007-09-28 | Leo Pharma As | Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions |
| US20040072728A1 (en) * | 2002-06-26 | 2004-04-15 | Fawwaz Rashid A. | Use of streptavidin to inhibit transplant rejection |
| ATE520400T1 (en) * | 2002-11-21 | 2011-09-15 | Genzyme Corp | COMBINATION OF A DIAMIDE DERIVATIVE AND IMMUNOSUPRESSIVES FOR SUPPRESSING TRANSPLANT REJECTION |
| AU2003291134A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Use of diamide derivatives for inhibiting chronic tissue transplant rejection |
-
2003
- 2003-11-21 AU AU2003291134A patent/AU2003291134A1/en not_active Abandoned
- 2003-11-21 DE DE60335652T patent/DE60335652D1/en not_active Expired - Lifetime
- 2003-11-21 EP EP03783726A patent/EP1567138B1/en not_active Expired - Lifetime
- 2003-11-21 JP JP2004555563A patent/JP4928079B2/en not_active Expired - Fee Related
- 2003-11-21 WO PCT/US2003/037318 patent/WO2004047825A1/en not_active Ceased
- 2003-11-21 ES ES03783726T patent/ES2363914T3/en not_active Expired - Lifetime
- 2003-11-21 PT PT03783726T patent/PT1567138E/en unknown
- 2003-11-21 AT AT03783726T patent/ATE493980T1/en not_active IP Right Cessation
- 2003-11-21 US US10/719,055 patent/US7687530B2/en not_active Expired - Lifetime
-
2010
- 2010-01-06 US US12/683,157 patent/US20100256211A1/en not_active Abandoned
- 2010-09-17 JP JP2010210237A patent/JP2010280725A/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004047825A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100256211A1 (en) | 2010-10-07 |
| AU2003291134A1 (en) | 2004-06-18 |
| US20040163654A1 (en) | 2004-08-26 |
| JP2006514013A (en) | 2006-04-27 |
| DE60335652D1 (en) | 2011-02-17 |
| WO2004047825A1 (en) | 2004-06-10 |
| PT1567138E (en) | 2011-04-11 |
| JP4928079B2 (en) | 2012-05-09 |
| US7687530B2 (en) | 2010-03-30 |
| JP2010280725A (en) | 2010-12-16 |
| EP1567138B1 (en) | 2011-01-05 |
| ATE493980T1 (en) | 2011-01-15 |
| ES2363914T3 (en) | 2011-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100256211A1 (en) | Inhibition of Chronic Tissue Transplant Rejection | |
| CN1124135C (en) | Use of rapamycin derivatives in vasculopathies and xenotransplantation | |
| WO2003086391A1 (en) | New use | |
| JP2000507224A (en) | Use of CSAID compounds as inhibitors of angiogenesis | |
| SK170999A3 (en) | Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent | |
| US7678822B2 (en) | Induction of immune tolerance | |
| JPWO2013147161A1 (en) | Nipecotic acid derivative and its pharmaceutical use | |
| AU2020266947A1 (en) | Method for treating endometriosis-associated pain by using diaminopyrimidine compound | |
| JP6878418B2 (en) | How to treat graft rejection | |
| MXPA04008888A (en) | Use of rapamycin for inhibiting of cell death. | |
| US5786376A (en) | Methods of treating opportunistic infections with azaspiranes | |
| KR100540537B1 (en) | Treatment of cirrhosis | |
| KR100616020B1 (en) | Use of Rapamycin Derivatives in Vasculopathies and Xenotransplantation | |
| HK40082113A (en) | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | |
| JPH10503202A (en) | Treatment of opportunistic infections with azaspirans | |
| HK1018688B (en) | Use of rapamycin derivatives in vasculopqthies and xenotransplantation | |
| JP2002201129A (en) | Agent for extraocular inflammatory disease | |
| CZ284327B6 (en) | The use of riluzol or pharmaceutically acceptable salts thereof for preparing medicaments | |
| IE83628B1 (en) | Topical compositions comprising benzimidazoles and benzotriazoles | |
| HK1164884A (en) | Prophylactic or therapeutic agent for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivative or salt thereof as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050531 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20080711 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/06 20060101ALI20100705BHEP Ipc: A61K 31/417 20060101AFI20100705BHEP |
|
| RTI1 | Title (correction) |
Free format text: USE OF A DIAMIDE DERIVATIVE FOR INHIBITING CHRONIC TRANSPLANT REJECTION |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 60335652 Country of ref document: DE Date of ref document: 20110217 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 60335652 Country of ref document: DE Effective date: 20110217 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20110404 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110406 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2363914 Country of ref document: ES Kind code of ref document: T3 Effective date: 20110819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110405 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 |
|
| 26N | No opposition filed |
Effective date: 20111006 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60335652 Country of ref document: DE Effective date: 20111006 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111130 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111121 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110105 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20180914 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20181114 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20181120 Year of fee payment: 16 Ref country code: IE Payment date: 20181109 Year of fee payment: 16 Ref country code: DE Payment date: 20181106 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20181203 Year of fee payment: 16 Ref country code: GB Payment date: 20181121 Year of fee payment: 16 Ref country code: TR Payment date: 20181102 Year of fee payment: 16 Ref country code: FR Payment date: 20181011 Year of fee payment: 16 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60335652 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20191201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200624 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191130 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20191121 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200603 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191121 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191121 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20210527 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191122 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191121 |